基于影像组学机器学习分类器在标准腹部CT上检测2型糖尿病:一项概念验证研究
本研究从422例2型糖尿病患者和456例年龄匹配对照者的标准腹部CT中提取胰腺影像组学特征,训练XGBoost模型并在测试集评估。模型在测试集上AUC为0.65,敏感度0.62、特异度0.61,能检测T2D的CT影像特征,但性能中等,需进一步优化验证。
要点
- 胰腺影像组学模型可在标准腹部CT上识别T2D影像特征,AUC 0.65。
- 模型性能在性别、CT层厚和CT厂商间无显著差异(p>0.05)。
- 误分类与正确分类患者的T2D病程、治疗方式及疗程无差异。
局限性
- 概念验证研究,样本量有限,需外部验证。
- 模型性能中等(AUC 0.65),敏感度和特异度约0.6。
- 仅基于胰腺影像组学特征,未纳入临床变量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To determine if pancreas radiomics-based AI model can detect the CT imaging signature of type 2 diabetes (T2D).
METHODS: Total 107 radiomic features were extracted from volumetrically segmented normal pancreas in 422 T2D patients and 456 age-matched controls. Dataset was randomly split into training (300 T2D, 300 control CTs) and test subsets (122 T2D, 156 control CTs). An XGBoost model trained on 10 features selected through top-K-based selection method and optimized through threefold cross-validation on training subset was evaluated on test subset.
RESULTS: Model correctly classified 73 (60%) T2D patients and 96 (62%) controls yielding F1-score, sensitivity, specificity, precision, and AUC of 0.57, 0.62, 0.61, 0.55, and 0.65, respectively. Model's performance was equivalent across gender, CT slice thicknesses, and CT vendors (p values > 0.05). There was no difference between correctly classified versus misclassified patients in the mean (range) T2D duration [4.5 (0-15.4) versus 4.8 (0-15.7) years, p = 0.8], antidiabetic treatment [insulin (22% versus 18%), oral antidiabetics (10% versus 18%), both (41% versus 39%) (p > 0.05)], and treatment duration [5.4 (0-15) versus 5 (0-13) years, p = 0.4].
CONCLUSION: Pancreas radiomics-based AI model can detect the imaging signature of T2D. Further refinement and validation are needed to evaluate its potential for opportunistic T2D detection on millions of CTs that are performed annually.
引用
- Wright, Mukherjee, Patra, et al. Radiomics-based machine learning (ML) classifier for detection of type 2 diabetes on standard-of-care abdomen CTs: a proof-of-concept study. Abdom Radiol (NY). 2022. PMID: 36085379. doi:10.1007/s00261-022-03668-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。